IP Library › Granted Patent US 12,723,282
Granted Patent B2
US 12,723,282 · App. 18/673,186 · Granted Sep 1, 2026

Multiplex detection of vulvovaginal candidiasis, trichomoniasis and bacterial vaginosis

Inventors: Nancy Paquette (Quebec, CA); Marie-Helene Tremblay (Quebec, CA); Simon Tremblay (Quebec, CA); Roseline Therrien (Quebec, CA); Marie-Christine Fortin (Quebec, CA); Lucile Belley-Montfort (Quebec, CA); Dany Cantin (Quebec, CA); Celine Roger-Dalbert (Quebec, CA)
Assignee: AUGUSTA SPINCO CORPORATION
C12Q1/689C12Q1/68C12Q1/6883C12Q1/6893C12Q1/6895
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,723,282
App. No.
18/673,186
Granted
Sep 1, 2026
Kind
B2
Abstract

Methods and compositions for detection of vulvovaginal candidiasis (VVC), trichomoniasis and bacterial vaginosis (BV) are disclosed herein. In some embodiments, the presence or absence of VVC-associated Candida, Trichomonas valginalis , and a plurality of BV-related bacteria in a sample is determined using multiplex nucleic acid-based testing methods.

Claims (39)

1 . A kit for detecting a bacterial vaginosis (BV)-related bacteria in a biological sample, wherein the BV-related bacteria is selected from the group consisting of: Lactobacillus crispatus, Lactobacillus jensenii, Gardnerella vaginalis, Atopobium vaginae, Megasphaera Type 1, BVAB2, and a combination thereof, the kit comprising:

(a) at least one pair of primers capable of hybridizing to the 16S rRNA gene of Atopobium vaginae , wherein each primer in said at least one pair of primers comprises a sequence of SEQ ID NO: 1 or SEQ ID NO: 2, or sequence differing by only one nucleotide mismatch relative to SEQ ID NO: 1 or SEQ ID NO: 2; and

an oligonucleotide probe comprising a sequence of SEQ ID NO: 3, or a sequence differing by only one nucleotide mismatch relative to SEQ ID NO: 3,

(b) at least one pair of primers capable of hybridizing to the 16S rRNA gene of BVAB2, wherein each primer in said at least one pair of primers comprises a sequence of SEQ ID NO: 4 or SEQ ID NO: 5, or a sequence differing by only one nucleotide mismatch relative to SEQ ID NO: 4 or SEQ ID NO: 5; and

an oligonucleotide probe comprising a sequence of SEQ ID NO: 6, or a sequence differing by only one nucleotide mismatch relative to SEQ ID NO: 6,

(c) at least one pair of primers capable of hybridizing to the 16S rRNA gene of Megasphaera type 1, wherein each primer in said at least one pair of primers comprises a sequence of SEQ ID NO: 7 or SEQ ID NO: 8, or a sequence differing by only one nucleotide mismatch relative to SEQ ID NO: 7 or SEQ ID NO: 8; and

an oligonucleotide probe comprising a sequence of SEQ ID NO: 9, or a sequence differing by only one nucleotide mismatch relative to SEQ ID NO: 9,

(d) at least one pair of primers capable of hybridizing to the vly gene of Gardnerella vaginalis , wherein each primer in said at least one pair of primers comprises a sequence selected from the group consisting of SEQ ID NOS: 10-12, or a sequence differing by only one nucleotide mismatch relative to a sequence selected from the group consisting of SEQ ID NOS: 10-12; and

an oligonucleotide probe comprising a sequence of SEQ ID NO: 13, or a sequence differing by only one nucleotide mismatch relative to SEQ ID NO: 13, and

(e) at least one pair of primers capable of hybridizing to the 16S rRNA genes of Lactobacillus crispatus and Lactobacillus jensenii , wherein each primer in said at least one pair of primers comprises a sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or a sequence differing by only one nucleotide mismatch relative to SEQ ID NO: 14 or SEQ ID NO: 15; and

an oligonucleotide probe comprising a sequence of SEQ ID NO: 16, or a sequence differing by only one nucleotide mismatch relative to SEQ ID NO: 16,

wherein each of the oligonucleotide probes of (a), (b), (c), (d) and (e) comprises a detectable moiety selected from the group consisting of a fluorescence emitter moiety, a fluorescence quencher moiety, a fluorophore, biotin, radionucleotides, radioactive label, and a chemiluminescent agent.

2 . The kit of claim 1 , wherein

(a) the at least one pair of primers capable of hybridizing to the 16S rRNA gene of Atopobium vaginae comprises a primer comprising the sequence of SEQ ID NO: 1 and a primer comprising the sequence of SEQ ID NO: 2; and

the oligonucleotide probe comprises the sequence of SEQ ID NO: 3,

(b) the at least one pair of primers capable of hybridizing to the 16S rRNA gene of BVAB2 comprises a primer comprising the sequence of SEQ ID NO: 4 and a primer comprising the sequence of SEQ ID NO: 5; and

the oligonucleotide probe comprises the sequence of SEQ ID NO: 6,

(c) the at least one pair of primers capable of hybridizing to the 16S rRNA gene of Megasphaera type 1 comprises a primer comprising the sequence of SEQ ID NO: 7 and a primer comprising the sequence of SEQ ID NO: 8; and

the oligonucleotide probe comprises the sequence of SEQ ID NO: 9,

(d) the at least one pair of primers capable of hybridizing to the vly gene of Gardnerella vaginalis comprises a primer comprising the sequence of SEQ ID NO: 10 or SEQ ID NO: 11 and a primer comprising the sequence of SEQ ID NO: 12; and

the oligonucleotide probe comprises the sequence of SEQ ID NO: 13, and/or

(e) the at least one pair of primers capable of hybridizing to the 16S rRNA genes of Lactobacillus crispatus and Lactobacillus jensenii comprises a primer comprising the sequence of SEQ ID NO: 14 and a primer comprising the sequence of SEQ ID NO: 15; and

the oligonucleotide probe comprises the sequence of SEQ ID NO: 16.

3 . A method to detect a bacterial vaginosis (BV)-related bacteria in a biological sample, wherein the BV-related bacteria is selected from the group consisting of: Lactobacillus crispatus, Lactobacillus jensenii, Gardnerella vaginalis, Atopobium vaginae, Megasphaera Type 1, BVAB2, and a combination thereof, comprising:

providing the kit of claim 1 ;

contacting said biological sample with the (a), (b), (c), (d) and (e) of the kit,

generating amplicons of the 16S rRNA sequences of Atopobium vaginae , BVAB2 , Megasphaera type 1, Lactobacillus crispatus and Lactobacillus jensenii , and/or amplicons of the vly gene sequence of Gardnerella vaginalis from said biological sample, if said sample comprises one or more of the BV-related bacteria; and

determining the presence or amount of one or more amplified products as an indication of the presence of one or more of the BV-related bacteria in said biological sample.

4 . The method of claim 3 , wherein said biological sample is a clinical sample.

5 . The method of claim 3 , wherein said biological sample is collected from the urethra, penis, anus, throat, cervix, or vagina.

6 . The method of claim 3 , wherein generating amplicons is carried out using a method selected from the group consisting of: polymerase chain reaction (PCR), ligase chain reaction (LCR), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), replicase-mediated amplification, Immuno-amplification, nucleic acid sequence based amplification, self-sustained sequence replication, rolling circle amplification, and transcription-mediated amplification (TMA).

7 . The method of claim 6 , wherein the PCR is real-time PCR.

8 . The kit of claim 1 , further comprising a DNA polymerase and/or a plurality of dNTPs.

9 . The kit of claim 1 , wherein the at least one pair of primers capable of hybridizing to the 16S rRNA gene of Atopobium vaginae comprises a primer comprising the sequence of SEQ ID NO: 1 and a primer comprising the sequence of SEQ ID NO: 2.

10 . The kit of claim 1 , wherein the at least one pair of primers capable of hybridizing to the 16S rRNA gene of BVAB2 comprises a primer comprising the sequence of SEQ ID NO: 4 and a primer comprising the sequence of SEQ ID NO: 5.

11 . The kit of claim 1 , wherein the at least one pair of primers capable of hybridizing to the 16S rRNA gene of Megasphaera type 1 comprises a primer comprising the sequence of SEQ ID NO: 7 and a primer comprising the sequence of SEQ ID NO: 8.

12 . The kit of claim 1 , wherein the at least one pair of primers capable of hybridizing to the vly gene of Gardnerella vaginalis comprises a primer comprising the sequence of SEQ ID NO: 10 or SEQ ID NO: 11 and a primer comprising the sequence of SEQ ID NO: 12.

13 . The kit of claim 1 , wherein the at least one pair of primers capable of hybridizing to the 16S rRNA genes of Lactobacillus crispatus and Lactobacillus jensenii comprises a primer comprising the sequence of SEQ ID NO: 14 and a primer comprising the sequence of SEQ ID NO: 15.

14 . The kit of claim 1 , wherein each primer is attached to a fluorophore at the 5′ end, or a fluorescence quencher at the 3′ end, or both.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2026
From: BECTON, DICKINSON AND COMPANY
To: AUGUSTA SPINCO CORPORATION
Reel/Frame 075860/0505 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2024
From: PAQUETTE, NANCY; TREMBLAY, MARIE-HELENE; TREMBLAY, SIMON; THERRIEN, ROSELINE; FORTIN, MARIE-CHRISTINE; BELLEY -MONTFORT, LUCILE; CANTIN, DANY; ROGER-DALBERT, CELINE
To: BECTON, DICKINSON AND COMPANY
Reel/Frame 067654/0343 →
Continuity (5)
Continuation 17370923 · Jul 8, 2021
Division 15567051 · Apr 20, 2016
Provisional Application 62279220 · Jan 15, 2016
Provisional Application 62152754 · Apr 24, 2015
Related Publication 20240368709A1 · Nov 7, 2024
References Cited (100)
US 3649454A · Isono et al. · 1972 [cited by applicant]
US 3716452A · Kitamura et al. · 1973 [cited by applicant]
US 4683195A · Mullis et al. · 1987 [cited by applicant]
US 4683202A · Mullis · 1987 [cited by applicant]
US 4800159A · Mullis et al. · 1989 [cited by applicant]
US 4988617A · Landegren et al. · 1991 [cited by applicant]
US 5130238A · Malek et al. · 1992 [cited by applicant]
US 5185242A · Keating et al. · 1993 [cited by applicant]
US 5399491A · Kacian et al. · 1995 [cited by applicant]
US 5427930A · Birkenmeyer et al. · 1995 [cited by applicant]
US 5455166A · Walker · 1995 [cited by applicant]
US 5849478A · Cashman · 1998 [cited by applicant]
US 5854033A · Lizardi · 1998 [cited by applicant]
US 6410278B1 · Notomi et al. · 2002 [cited by applicant]
US 6977148B2 · Dean et al. · 2005 [cited by applicant]
US 7494771B2 · Picard et al. · 2009 [cited by applicant]
US 7625704B2 · Fredricks et al. · 2009 [cited by applicant]
US 8067207B2 · Bergeron et al. · 2011 [cited by applicant]
US 11098376B2 · Paquette · 2021 [cited by examiner]
US 12037649B2 · Paquette et al. · 2024 [cited by applicant]
US 20070178495A1 · Fredricks et al. · 2007 [cited by applicant]
US 20100075306A1 · Bretelle · 2010 [cited by examiner]
US 20130288988A1 · Cartwright et al. · 2013 [cited by applicant]
US 20130316922A1 · Balashov et al. · 2013 [cited by applicant]
US 20140030710A1 · Stevens · 2014 [cited by applicant]
US 20140127684A1 · Bergeron et al. · 2014 [cited by applicant]
US 20140302500A1 · Getman et al. · 2014 [cited by applicant]
US 20150104805A1 · Mc Millian · 2015 [cited by applicant]
WO WO2003008636 · 2003 [cited by applicant]
WO WO2008062136 · 2008 [cited by applicant]
WO WO2010083274 · 2010 [cited by applicant]
WO WO2011103274 · 2011 [cited by applicant]
WO WO2012149034 · 2012 [cited by applicant]
Canadian Office Action dated May 1, 2025 in Canadian Application No. 3,224,392. [cited by applicant]
Extended European Search Report dated Feb. 5, 2025 in EP Application No. 24174382.2. [cited by applicant]
Eddouzi et al., “Characterization of a New Clinical Yeast Species, [cited by applicant]
Amsel et al., “Nonspecific vaginitis: Diagnostic criteria and microbial and epidemiologic associations,” Am. J. Med. 1983, 74(1), 14-22. [cited by applicant]
Cartwright et al., “Development and Validation of a Semiquantitative, Multitarget PCR Assay for Diagnosis of Bacterial Vaginosis,” Journal of Clinical Microbiology 2012, 50(7), 2321-2329. [cited by applicant]
De Backer et al., “Quantitative determination by real-time PCR of four vaginal [cited by applicant]
Decision to Grant dated May 3, 2024 in European Patent Application No. 22200785.8. [cited by applicant]
Diba, Kambiz, et al. “Rapid identification of drug resistant [cited by applicant]
Examination Report dated Apr. 14, 2021 in European Patent Application No. 16783760.8. [cited by applicant]
Examination Report dated Apr. 21, 2021 in Australian Patent Application No. 2020205314. [cited by applicant]
Examination Report dated Apr. 28, 2020 in Australian Patent Application No. 2016252551. [cited by applicant]
Examination Report dated Dec. 23, 2021 in European Patent Application No. 16783760.8. [cited by applicant]
Examination Report dated Jun. 10, 2020 in European Patent Application No. 16783760.8. [cited by applicant]
Examination Report dated Jun. 13, 2024 in Australian Patent Application 2023201615. [cited by applicant]
Examination Report dated May 7, 2024 in Australian Patent Application 2023201615. [cited by applicant]
Examination Report dated Nov. 22, 2022 in Australian Patent Application No. 2021286250. [cited by applicant]
Examination Report dated Nov. 5, 2019 in Australian Patent Application No. 2016252551. [cited by applicant]
Extended European Search Reported dated Mar. 3, 2023 in European Patent Application No. 22200785.8. [cited by applicant]
Extended European Search Reported dated Nov. 11, 2024 in European Patent Application No. 24174382.2.2. [cited by applicant]
Extended European Search Reported dated Nov. 28, 2018 in European Patent Application No. 16783760.8. [cited by applicant]
Ezaki et al., “Achromopeptidase for lysis of anaerobic gram-positive cocci,” J Clin Microbiol. 1982, 16(5), 844-846. [cited by applicant]
Final Office Action dated Jun. 18, 2020 in U.S. Appl. No. 15/567,051. [cited by applicant]
Fredricks et al., “Targeted PCR for Detection of Vaginal Bacteria Associated with Bacterial Vaginosis,” J. Clin. Microbiol. 2007, 45(10), 3270-3276. [cited by applicant]
International Search Report and Written Opinion dated Aug. 11, 2016 in PCT Application No. PCT/US2016/028433. [cited by applicant]
Lizardi et al., “Exponential Amplification of Recombinant-RNA Hybridization Probes” Bio/Technology 1988, 6, 1197-1202. [cited by applicant]
Menard et al., “Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis,” Clin Infect Dis. 2008, 47(1), 33-43. [cited by applicant]
Mullis et al., “Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction,” Methods Enzymol. 1987, 155, 335-350. [cited by applicant]
Non-Final Office Action Dated Dec. 14, 2023 in U.S. Appl. No. 17/370,923. [cited by applicant]
Non-Final Office Action dated Dec. 23, 2019 in U.S. Appl. No. 15/567,051. [cited by applicant]
Non-Final Office Action dated Dec. 28, 2020 in U.S. Appl. No. 15/567,051. [cited by applicant]
Notice of Allowance dated Dec. 22, 2022 in European Patent Application No. 16783760.8. [cited by applicant]
Notice of Allowance dated Dec. 22, 2022, in Australian Patent Application No. 2021286250. [cited by applicant]
Notice of Allowance dated Feb. 18, 2022, in Australian Patent Application No. 2020205314. [cited by applicant]
Notice of Allowance Dated Jan. 16, 2024 in European Patent Application 22200785.8. [cited by applicant]
Notice of Allowance dated Jul. 21, 2021, in U.S. Appl. No. 15/567,051. [cited by applicant]
Notice of Allowance dated Jun. 15, 2021, in U.S. Appl. No. 15/567,051. [cited by applicant]
Notice of Allowance dated Jun. 19, 2023 in Korean Patent Application No. 10-2017-7032958. [cited by applicant]
Notice of Allowance dated Jun. 22, 2020, in Australian Patent Application No. 2016252551. [cited by applicant]
Notice of Allowance Dated Jun. 4, 2024 in U.S. Appl. No. 17/370,923. [cited by applicant]
Notice of Allowance Dated Mar. 20, 2024 in U.S. Appl. No. 17/370,923. [cited by applicant]
Notice of Allowance Dated Mar. 27, 2024 in U.S. Appl. No. 17/370,923. [cited by applicant]
Notice of Allowance dated Oct. 5, 2021, in Australian Patent Application No. 2020205314. [cited by applicant]
Nugent et al., “Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation,” Journal of Clinical Microbiology 1991, 29(2), 297-301. [cited by applicant]
Office Action dated Apr. 23, 2024 in Korean Patent Application No. 10-2023-7026463. [cited by applicant]
Office Action dated Dec. 22, 2022 in Korean Patent Application No. 10-2017-7032958. [cited by applicant]
Office Action dated Dec. 8, 2022 in Canadian Patent Application No. 2,982,467. [cited by applicant]
Office Action Dated Feb. 29, 2024 in Brazilian Patent Application No. BR112017022379-1. [cited by applicant]
Office Action dated Jan. 19, 2022 in Canadian Patent Application No. 2,982,467. [cited by applicant]
Office Action dated Jan. 7, 2020 in Brazilian Patent Application No. BR112017022379-1. [cited by applicant]
Office Action dated Jun. 21, 2022 in Korean Patent Application No. 10-2017-7032958. [cited by applicant]
Office Action Dated Oct. 25, 2023 in U.S. Appl. No. 17/370,923. [cited by applicant]
Paule et al., “Direct Detection of [cited by applicant]
Pleckaityte et al., “Genetic and biochemical diversity of Gardnerella vaginalis strains isolated from women with bacterial vaginosis,” FEMS Immunol Med Microbiol 2012, 65, 69-77. [cited by applicant]
Rad, et al. “Identification of Candida Species Associated with Vulvovaginal Candidiasis by Multiplex PCR”, Infectious Diseases in Obstetrics and Gynecology, 2012, vol. 2012, 1-5. [cited by applicant]
Restriction Requirement dated Jul. 25, 2017 in U.S. Appl. No. 15/567,051. [cited by applicant]
Savochkina, et al., “The Development of Technique of Diagnostic of Vuvlvovaginal Candidiasis Based on Quantitative Multiplex Polymerase Chain Reaction”, Klin Lab Diagn, 2015, 60(4), 55-62. [cited by applicant]
Sha et al., “Utility of Amsel criteria, Nugent score, and quantitative PCR for Gardnerella vaginalis, Mycoplasma hominis, and [cited by applicant]
Shipitsyna et al., “Composition of the Vaginal Microbiota in Women of Reproductive Age—Sensitive and Specific Molecular Diagnosis of Bacterial Vaginosis Is Possible?” Plos One 2013, 8(4), e60670. [cited by applicant]
Technical Examination Report dated Oct. 10, 2023 in Brazilian Patent Application No. BR1120170223791. [cited by applicant]
Zariffard et al., “Detection of bacterial vaginosis-related organisms by real-time PCR for Lactobacilli, Gardnerella vaginalis and Mycoplasma hominis,” FEMS Immunol Med Microbiol. 2002, 34(4), 277-81. [cited by applicant]
Zozaya-Hinchliffe et al., “Quantitative PCR assessments of bacterial species in women with and without bacterial vaginosis,” J Clin Microbiol. 2010, 48(5), 1812-9. [cited by applicant]
Zvirbliene, Aurelija, et al. “Production and characterization of monoclonal antibodies against vaginolysin: Mapping of a region critical for its cytolytic activity.” Toxicon 56.1 (2010): 19-28. [cited by applicant]
Fredricks et al., “Targeted PCR for Detection of Vaginal Bacteria Associated with Bacterial Vaginosis,” Journal of Clinical Microbiology 2007, 45(10), 3270-3276. [cited by applicant]
Notice of Allowance dated Dec. 30, 2024 in Korean Patent Application No. 10-2023-7026463. [cited by applicant]
Restriction Requirement dated Aug. 25, 2023 in U.S. Appl. No. 17/370,923. [cited by applicant]
Examination Report dated Dec. 15, 2025 in European Patent Application No. 24174382.2. [cited by applicant]
Partial European Search Report dated Nov. 11, 2024 in European Patent Application No. 24174382.2. [cited by applicant]